Saturday 21 December 2024
Internal Reference Number: FOI_6649
Date Request Received: 22/06/2022 00:00:00
Date Request Replied To: 14/07/2022 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer
Request Category: Companies
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent • Atezolizumab +Nab-paclitaxel/Paclitaxel • Capecitabine as a single agent • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Lapatinib • Neratinib • Parp Inhibitors (Olaparib/Talazoparib) • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Palbociclib + Fulvestrant • Pembrolizumab • Platinum (e.g. carboplatin or cisplatin) as a single agent • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Taxane and/or Anthracycline in combination • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Transtuzumab deruxtecan • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: Please note, any numbers less than or equal to 5 have been suppressed in order to protect patient confidentiality, as per Information Governance regulations. • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 0 • Abemaciclib + Fulvestrant <5 • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0 • Atezolizumab +Nab-paclitaxel/Paclitaxel 0 • Capecitabine as a single agent 9 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane <5 • Fulvestrant as a single agent 0 • Lapatinib 0 • Neratinib <5 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 34 • Palbociclib + Fulvestrant <5 • Pembrolizumab 0 • Platinum (e.g. carboplatin or cisplatin) as a single agent 0 • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 0 • Ribociclib + Fulvestrant 0 • Sacituzumab Govitecan 0 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent <5 • Taxane and/or Anthracycline in combination 34 • Trastuzumab as a single agent or in combination 39 • Trastuzumab emtansine 6 • Transtuzumab deruxtecan <5 • Any other active systemic anti-cancer therapy <5 | |
| Question Number 2: In the past 3 months, how many early/locally advanced breast cancer (Stages 1 to 3B) patients were treated with: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Taxane and/or Anthracycline (monotherapy or in combination) • Any other active systemic anti-cancer therapy | |
| Answer To Question 2: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 0 • Taxane and/or Anthracycline (monotherapy or in combination) 14 • Any other active systemic anti-cancer therapy 58 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
